155 related articles for article (PubMed ID: 33467653)
1. Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women.
Eriksson M; Czene K; Conant EF; Hall P
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33467653
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial.
Eriksson M; Eklund M; Borgquist S; Hellgren R; Margolin S; Thoren L; Rosendahl A; Lång K; Tapia J; Bäcklund M; Discacciati A; Crippa A; Gabrielson M; Hammarström M; Wengström Y; Czene K; Hall P
J Clin Oncol; 2021 Jun; 39(17):1899-1908. PubMed ID: 33734864
[TBL] [Abstract][Full Text] [Related]
3. Derived mammographic masking measures based on simulated lesions predict the risk of interval cancer after controlling for known risk factors: a case-case analysis.
Hinton B; Ma L; Mahmoudzadeh AP; Malkov S; Fan B; Greenwood H; Joe B; Lee V; Strand F; Kerlikowske K; Shepherd J
Med Phys; 2019 Mar; 46(3):1309-1316. PubMed ID: 30697755
[TBL] [Abstract][Full Text] [Related]
4. Mammographic density, endocrine therapy and breast cancer risk: a prognostic and predictive biomarker review.
Atakpa EC; Thorat MA; Cuzick J; Brentnall AR
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013091. PubMed ID: 34697802
[TBL] [Abstract][Full Text] [Related]
5. [Tailored Breast Screening Trial (TBST)].
Paci E; Mantellini P; Giorgi Rossi P; Falini P; Puliti D;
Epidemiol Prev; 2013; 37(4-5):317-27. PubMed ID: 24293498
[TBL] [Abstract][Full Text] [Related]
6. Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.
Gabrielson M; Hammarström M; Bäcklund M; Bergqvist J; Lång K; Rosendahl AH; Borgquist S; Hellgren R; Czene K; Hall P
Int J Cancer; 2023 Jun; 152(11):2362-2372. PubMed ID: 36637153
[TBL] [Abstract][Full Text] [Related]
7. Mammographic density changes following discontinuation of tamoxifen in premenopausal women with oestrogen receptor-positive breast cancer.
Kim WH; Cho N; Kim YS; Yi A
Eur Radiol; 2018 Aug; 28(8):3176-3184. PubMed ID: 29626240
[TBL] [Abstract][Full Text] [Related]
8. Mammographic features associated with interval breast cancers in screening programs.
Boyd NF; Huszti E; Melnichouk O; Martin LJ; Hislop G; Chiarelli A; Yaffe MJ; Minkin S
Breast Cancer Res; 2014 Aug; 16(4):417. PubMed ID: 25346388
[TBL] [Abstract][Full Text] [Related]
9. Influence of mammographic parenchymal pattern in screening-detected and interval invasive breast cancers on pathologic features, mammographic features, and patient survival.
Porter GJ; Evans AJ; Cornford EJ; Burrell HC; James JJ; Lee AH; Chakrabarti J
AJR Am J Roentgenol; 2007 Mar; 188(3):676-83. PubMed ID: 17312053
[TBL] [Abstract][Full Text] [Related]
10. Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk for Screen-Detected and Interval Cancers: A Case-Control Study.
Kerlikowske K; Scott CG; Mahmoudzadeh AP; Ma L; Winham S; Jensen MR; Wu FF; Malkov S; Pankratz VS; Cummings SR; Shepherd JA; Brandt KR; Miglioretti DL; Vachon CM
Ann Intern Med; 2018 Jun; 168(11):757-765. PubMed ID: 29710124
[TBL] [Abstract][Full Text] [Related]
11. Association of the Interaction Between Mammographic Breast Density, Body Mass Index, and Menopausal Status With Breast Cancer Risk Among Korean Women.
Tran TXM; Moon SG; Kim S; Park B
JAMA Netw Open; 2021 Dec; 4(12):e2139161. PubMed ID: 34940866
[TBL] [Abstract][Full Text] [Related]
12. Association of Longitudinal Mammographic Breast Density Changes with Subsequent Breast Cancer Risk.
Tran TXM; Kim S; Song H; Lee E; Park B
Radiology; 2023 Feb; 306(2):e220291. PubMed ID: 36125380
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of screening mammography by density and texture: a cohort study from a population-based screening program in Denmark.
von Euler-Chelpin M; Lillholm M; Vejborg I; Nielsen M; Lynge E
Breast Cancer Res; 2019 Oct; 21(1):111. PubMed ID: 31623646
[TBL] [Abstract][Full Text] [Related]
14. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
15. Family History of Breast Cancer and Mammographic Breast Density in Premenopausal Women.
Han Y; Moore JX; Colditz GA; Toriola AT
JAMA Netw Open; 2022 Feb; 5(2):e2148983. PubMed ID: 35175341
[TBL] [Abstract][Full Text] [Related]
16. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers.
Mandelson MT; Oestreicher N; Porter PL; White D; Finder CA; Taplin SH; White E
J Natl Cancer Inst; 2000 Jul; 92(13):1081-7. PubMed ID: 10880551
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study.
Cuzick J; Warwick J; Pinney E; Duffy SW; Cawthorn S; Howell A; Forbes JF; Warren RM
J Natl Cancer Inst; 2011 May; 103(9):744-52. PubMed ID: 21483019
[TBL] [Abstract][Full Text] [Related]
18. Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT.
Duffy S; Vulkan D; Cuckle H; Parmar D; Sheikh S; Smith R; Evans A; Blyuss O; Johns L; Ellis I; Sasieni P; Wale C; Myles J; Moss S
Health Technol Assess; 2020 Oct; 24(55):1-24. PubMed ID: 33141657
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
